44 results
Keyword Botox - Polvere Remove keyword
-
List item
Referral: Botox
Clostridium botulinum type A neurotoxin complex, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 21/02/2003, EC decision date: 25/06/2003, Last updated: 16/10/2003Botox … Commission final decision Overview Botox [Clostridium botulinum toxin … membrane on cholinergic neurons. Botox was first licensed in the … -
List item
National expert: Vasileios Sakalis, European Medicines Agency (updated)
- Declaration of interests - 79.79 KB | PDF
- Curriculum Vitae - 21.08 KB | PDF
73(3):e60-62 Macroplastique and botox are superior to Macroplastique … -
List item
Human medicine European public assessment report (EPAR): NeuroBloc
botulinum toxin type B, Torticollis
Date of authorisation: 22/01/2001, Revision: 33, Authorised, Last updated: 16/11/2022 -
List item
Human medicine European public assessment report (EPAR): Nuceiva
Botulinum toxin type A, Skin Aging
Date of authorisation: 27/09/2019,
, Revision: 4, Authorised, Last updated: 10/06/2022
-
List item
Human medicine European public assessment report (EPAR): Aimovig
erenumab, Migraine Disorders
Date of authorisation: 26/07/2018,, Revision: 8, Authorised, Last updated: 01/03/2022
-
List item
Human medicine European public assessment report (EPAR): Vyepti
eptinezumab, Migraine Disorders
Date of authorisation: 24/01/2022, Revision: 2, Authorised, Last updated: 29/11/2022 -
List item
National expert: Astrid Thomas, European Medicines Agency (updated)
- Declaration of interests - 79.97 KB | PDF
- Curriculum Vitae - 55.73 KB | PDF
Amisulpride, Apomorfina, Botox, babinazumab Cabergolina … -
List item
Human medicine European public assessment report (EPAR): Jakavi (updated)
ruxolitinib (as phosphate), Myeloproliferative Disorders; Polycythemia Vera; Graft vs Host Disease
Date of authorisation: 23/08/2012, Revision: 27, Authorised, Last updated: 17/01/2023 -
List item
Human medicine European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna) (updated)
CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2), COVID-19 virus infection
Date of authorisation: 06/01/2021,
, , Revision: 35, Authorised, Last updated: 03/02/2023
-
List item
Human medicine European public assessment report (EPAR): Oxervate
Recombinant human nerve growth factor, Keratitis
Date of authorisation: 06/07/2017,, 
, 
, Revision: 1, Authorised, Last updated: 04/04/2022
-
List item
Human medicine European public assessment report (EPAR): Inrebic
fedratinib dihydrochloride monohydrate, Myeloproliferative Disorders; Primary Myelofibrosis
Date of authorisation: 08/02/2021,, , Revision: 3, Authorised, Last updated: 08/12/2021
-
List item
National expert: Francesco Onida, Italian Medicines Agency (updated)
- Declaration of interests - 81.89 KB | PDF
- Curriculum Vitae - 50.99 KB | PDF
-
List item
National expert: Francesco Rodeghiero, European Medicines Agency (updated)
- Declaration of interests - 82.47 KB | PDF
- Curriculum Vitae - 115.78 KB | PDF
-
List item
Referral: Xeomin
clostridium botulinum neurotoxin type A, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 19/07/2007, EC decision date: 24/10/2007, Last updated: 08/02/2008from the drug substance in Botox® and Dysport® in that it … of Xeomin was compared to Botox: - The paralytic activity … paralytic activity of Xeomin and Botox was assessed in the mouse … -
List item
Referral: Soludox
doxycycline hyclate, Article 13
Status: European Commission final decision, opinion/position date: 12/06/2013, EC decision date: 12/08/2013, Last updated: 24/09/2013Netherlands Soludox 500 mg/g polvere da somministrare nell’acqua … Netherlands Acquadox 500 mg/g polvere da somministrare nell’acqua … -
List item
Referral: Doxyfar 50%
doxycycline hyclate, associated names: Soludox 500 mg/g, Soludox Vet, Soludox 433 mg/g, Doxy Ort 50%, Article 34
Status: European Commission final decision, opinion/position date: 04/05/2011, EC decision date: 13/07/2011, Last updated: 24/08/2011Netherlands Soludox 500 mg/g polvere per uso in acqua di bevanda … Netherlands Soludox 500 mg/g polvere per uso in acqua di bevanda … -
List item
Referral: Losec
omeprazole, associated names: Antra, Logastric, Losec Forte, Mopral, Omeprazen, Omeprazole, AstraZeneca, Zoltum, Article 30 referrals
Status: European Commission final decision, opinion/position date: 20/01/2010, EC decision date: 10/06/2010, Last updated: 19/09/2011 -
List item
Referral: Strenzen 500/125-mg/g powder
amoxicillin, clavulanic acid, Article 33
Status: European Commission final decision, opinion/position date: 10/04/2013, EC decision date: 12/08/2013, Last updated: 19/09/2013STRENZEN 500/125 mg/g polvere per somministrazione in … -
List item
Referral: Bleomycin
bleomycin, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 19/12/2008, EC decision date: 12/03/2009, Last updated: 31/03/2009 -
List item
Referral: Girolan and its associated name Apralan
apramycin sulfate, associated names: Apralan, Article 34
Status: European Commission final decision, Last updated: 15/06/2018Italy Apralan Solubile polvere per soluzione orale per … -
List item
Referral: Veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and, or poultry
lincomycin, spectinomycin, associated names: Please see Annex I, Article 35
Status: European Commission final decision, opinion/position date: 19/05/2016, EC decision date: 22/08/2016, Last updated: 16/09/2016 -
List item
Referral: Linco-Spectin 100 and associated names
lincomycin, spectinomycin, Article 34
Status: European Commission final decision, opinion/position date: 10/04/2014, EC decision date: 11/07/2014, Last updated: 04/09/2014Roma Italy LINCOSPECTIN Polvere orale per uso in acqua da … -
List item
Referral: Colistin oral
colistin, Article 35
Status: European Commission final decision, opinion/position date: 11/12/2014, EC decision date: 16/03/2015, Last updated: 13/04/2015 -
List item
National expert: Marek Jutel, European Medicines Agency (updated)
- Declaration of interests - 82.39 KB | PDF
- Curriculum Vitae - 135.88 KB | PDF
-
List item
National expert: DELIA GOLETTI, Italian Medicines Agency (updated)
- Declaration of interests - 81.38 KB | PDF
- Curriculum Vitae - 87.87 KB | PDF